Using Cardiovascular Magnetic Resonance Tissue Characterisation and Wearable Technology to PREDICT Clinical Outcomes, Response to Therapy and Arrhythmias in Hospitalised Heart Failure Patients (PREDICT-HF)

All patients admitted to University Hospital Southampton with a new primary diagnosis of heart failure will be considered for the study.

The diagnosis of heart failure will be confirmed by a senior cardiologist with a subspecialty interest in heart failure following detailed review of the patient's history, clinical findings and investigations using the following diagnostic criteria:

1. Signs and symptoms of heart failure

   &

2. Objective evidence of cardiac dysfunction either by;

Left ventricular ejection fraction of ≤ 50%

or;

Plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) >400 pg/mL if in sinus rhythm or > 1000 pg/ml if in atrial fibrillation/flutter and being treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the time of inclusion.

Inclusion Criteria:

• Age ≥18
• First hospital admission with a diagnosis of HF (as defined below)
• Able and willing to provide informed consent
• Able to undergo CMR

Exclusion Criteria:

• Known or subsequent diagnosis of amyloidosis, sarcoidosis or hypertrophic cardiomyopathy
• Severe valve disease of any type requiring inpatient surgery
• Heart transplant recipient or admitted for cardiac transplantation/ left ventricular assist device
• Clinically apparent myocardial ischemia which requires revascularisation
• Myocardial infarction or revascularisation within the previous 60 days
• Intra cardiac mass which requires surgery
• Active endocarditis
• Septicaemia
• Pregnancy
• Life expectancy <2 years secondary to any other cause (i.e. malignancy)
• Active treatment with chemotherapy
• Severe renal failure (GFR <30)